LAVAL, Quebec—Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced yesterday that following the expiration on Oct. 14, 2015, of the tender offer to purchase all of the outstanding shares of Synergetics USA, Inc. (NASDAQ: SURG) that all shares that were validly tendered and not properly withdrawn were accepted for payment. The company expects to complete the acquisition of Synergetics through a merger without a vote of Synergetics stockholders pursuant to Section 251(h) of the Delaware General Corporation Law.

Valeant is acquiring Synergetics at a price per share of $6.50 plus up to $1.00 per share if specified milestones are achieved. As a result of the merger, Synergetics will become a wholly owned subsidiary of Valeant. Following completion of the merger, the common stock of Synergetics will no longer be listed for trading on the NASDAQ Capital Market.